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Our serological analysis of malignant melanoma has focused on cell surface antigens 
detected by reactions with autologous serum (1, 2). Cultured lines of melanoma cells and 
companion skin fibroblasts from the same individual serve as standard target cells in 
mixed hemadsorption (MHA) and immune adherence (IA) assays. Absorption tests with 
cells from autologous,  allogeneic, and xenogeneic sources determine the specificity of 
reactions observed between melanoma cells and autologous serum. In this way, three 
distinctive melanoma surface antigens, designated AU, BD, and AH, have been defined 
(1, 2). AU and BD belong to a class of individually  distinct surface antigens which show 
an absolute restriction to autologous melanoma cells (1, 2). The other, AH, represents a 
class of shared melanoma antigens which has been detected on 5 out of 12 melanomas, but 
not on corresponding autologous fibroblasts or on other normal or mahgnant ttssues (2) 
This report  summarizes  the  analysis of three  additional autologous serum 
reactions with melanoma cells. In the two instances where autologous fibroblast 
lines were  available as  target  cells,  these  did  not  react  in  direct  tests  with 
autologous serum,  thus  giving the  impression of melanoma  specificity.  How- 
ever,  absorption tests  indicated that  the  antigens being detected  occur  on  a 
range  of  other  cell  types,  including fibroblasts,  with  a  pattern  of  antigen 
distribution that is unique in our experience. 
Materials  and Methods 
T~ssue Culture.  For derivation of melanoma and other cell hnes, see our previous reports (1, 
2). Tissue culture hnes are maintained in Eagle's minimum  essential medium supplemented with 
2 mM glutamlne, 1% nonessential amino acids, pemcllhn 100 IU/ml, streptomycin 100 ~g/ml, and 
10-20% fetal bovine serum. 
Serology  IA and MHA assays were performed as descmbed previously (1, 2)  Titer refers to the 
highest dilution giving 10% positive cells m IA assays and 5% m  MHA assays  For absorption 
analysis (1, 2), cultured cells were harvested by mechamcal scraping or by 0 05% EDTA, prelimi- 
nary tests showed that the antigens being detected were not destroyed by EDTA at this concentra- 
tion  After removal of the absorbing cells by centrifugatlon, the serum was tltrated for residual 
reactivity on autologous melanoma cells. 
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Results 
Direct IA and MHA Assays  with Autologous  Melanoma  Cells  and Normal 
Skin Fibroblasts.  Sera from three patients  showing reactivity with cultured 
autologous melanoma cells were selected from our original survey (1, 2). Initial 
study indicated that IA was optimal for demonstrating reactions with AV and 
AN sera and MHA best for AT serum. AV and AT sera reacted most strongly at 
24°C, whereas AN serum showed optimal reactivity at 4°C. The titers of differ- 
ent  serum  specimens from these patients  ranged  from  1/4-1/16 for AV,  1/40- 
1/320 for AN, and 1/4-1/64 for AT sera. Cultures of skin fibroblasts were avail- 
able from patients AV and AT. Serum that was positive with autologous mela- 
noma cells did not react with autologous fibroblasts. 
Absorption Analysis 
AV SERUM.  Fig.  1 a  illustrates  a  single absorption test with the AV serum 
specimen selected for analysis, and Table I summarizes the results of a series of 
absorption  tests  with  this  serum.  In  contrast  to  negative  direct  tests  with 
autologous fibroblasts, the reactivity of AV serum with autologous melanoma 
was absorbed by autologous fibroblasts as well as autologous melanoma  cells. 
Autologous hematopoietic cells, however, failed to absorb reactivity, indicating 
that the antigen (or antigens) detected by this absorption system is present only 
on certain  differentiated  cell types.  AV antigen  also has characteristics  of an 
alloantigen; some allogeneic melanoma cells (e.g., SK-MEL-27 and SK-MEL-28) 
and  companion fibroblasts absorbed AV reactivity,  whereas comparable  cells 
from other individuals (e.g., SK-MEL-13 and SK-MEL-37) did not. The antigen 
occurs on the surface of xenogeneic cells as well; nucleated cells from monkey, 
chicken, and mouse absorbed reactivity from AV serum. Autologous, allogeneic, 
and xenogeneic erythrocytes lacked AV antigen. 
AN SERUM.  Fig.  1 b  and  Table II represent  absorption  analysis  of the  se- 
lected AN serum.  A  wide variety of cultured and noncultured  nucleated cells 
absorbed AN reactivity.  Unlike the AV system, the AN antigen  is present on 
lymphoid cells and granulocytes. However, like AV, it has characteristics of an 
alloantigen and also of a differentiation antigen (present on some tissues but not 
on  others  from  the  same  individual).  This  is  illustrated  by absorption  with 
various cell types from patient  BD; melanoma cells (SK-MEL-37),  companion 
fibroblasts, and platelets did not absorb AN reactivity, but lymphoid cells and 
granulocytes did.  AN antigen  is found also on some xenogeneic cells such  as 
cultured monkey kidney, but not on mouse or chicken fibroblasts. 
AT SERUM.  As shown in Fig. 1 c and Table III, the antigen defined by MHA 
reactions of the selected AT serum on autologous melanoma has been found on 
all  cultured  and  noncultured  nucleated  cell  populations  tested,  autologous, 
allogeneic,  or xenogeneic.  Erythrocytes are the only cell type lacking AT anti- 
gen. 
Discussion 
The choice of autologous target cells to search for antibody to surface antigens 
of melanoma cells was intended to limit the range of antibodies that could be 
detected,  excluding  therefore  the contribution  of alloantibodies present  natu- 786  SHIKU  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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FiG  1.  Examples of individual absorption tests  with AV, AN, and AT sera. (a) Autolo- 
gous melanoma and fibroblasts,  allogeneic lung cancer,  and xenogenelc  mouse fibroblasts 
absorbed  IA  reactivity  of  AV  serum  to  autologous  melanoma  SK-MEL-29.  Allogenelc 
melanoma SK-MEL-13  and allogeneic  lymphoid cells did not  (b) Autologous  melanoma, 
allogeneic  melanoma SK-MEL-27  and its companion fibroblast  hne,  allogenelc  lymphoid 
cells, and xenogeneic monkey kidney cells absorbed IA reactivity of AN serum to autologous 
melanoma  SK-MEL-21.  Allogeneic  melanoma  (SK-MEL-37),  type  AB  erythrocytes,  and 
xenogeneic mouse spleen cells did not.  (c) All nucleated cells tested absorbed MHA reactiv- 
Ity of AT serum to autologous  melanoma SK-MEL-27.  Type O erythrocytes and xenogenelc 
sheep erythrocytes  did not 
TABLE  I 
Absorption  of IA React~wty of A V Serum for Autologous  Melanoma SK-MEL-29 
Posltlve absorption  Negative absorphon 
Autologous 
Cultured melanoma ceils 
SK-MEL-29  (AV) 
Cultured  normal cells 
AV fibroblasts 
Allogenelc 
Cultured melanoma ceils 
SK-MEL.27  (AT1 
SK-MEL-28  (AU~ 
SK-MEL-30  ~AW} 
MeWo  (BD 




Cultured  nonmelanoma  cells 
SK-LMS- 1 (lelomyosarcoma) 
SK-RC-4 (renal cell  ca) 
T-24 (bladder ca) 
ME  180 (cervlcal  ca) 
SK-LC-LL  {lung ca) 
Xenogenelc 
Cultured monkey kldney cells 
Cultured  chlcken fibroblasts 
Cultured mouse fibroblasts 















Cultured melanoma cells 
SK-MEL-13  (AH) 
SK-MEL-37  (BD~ 
Cultured normal cells 
AH fibroblasts 
BD fibroblasts 
Xenogenelc  cells and serum 
Sheep erythrocytes 
Fetal bovine serum 
Mouse erythrocytes SHIKU  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE  II 
Absorption of lA Reactivity of AN Serum for Autologous Melanoma SK-MEL-21 
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Posltlve  abserptmn  Negatlve absorptmn 
Autologous  Allogenelc 
Cultured  melanoma cells  Cultured  nonmelanoma cells 
SK-MEL-21 (AN)  SK-LMS-1 (lelomyesarcoma) 
Allogenelc  Sal III (breast ca) 
Cultured  melanoma cells  HEp-2 (larynx ca) 
SK-MEL-13 (AH)  SK-LC-LL (lung ca) 
SK-MEL-19 (AL)  WI-38 (fetal lung fibmblasts) 
SK-MEL.27 (AT)  PHEL-6  (fetal  lung  fibro- 
SK-MEL-28 (AU)  blasts) 
MeWo  (BI)  Normal cells 
Cultured normal cells  Lymphmd cells  (including  BD) 
AH fibreblasts  Granulecytes (including  BD) 
AT fibroblasts  Xenogenelc 
Cultured monkey kldney cells 
Allogenem 
Cultured  melanoma cells 
SK-MEL-37 (BD) 




ME 180 (cervical ca) 




Xenogenelc cells  and serum 
Sheep erythrocytes 
Fetal bovine serum 
Mouse spleen cells 
Mouse erythrecytes 
Cultured mouse fibroblasts 
Cultured chlcken fibroblasts 
TABLE  III 
Absorptmn  of MHA Reactwity of AT Serum for Autologous  Melanoma SK-MEL-27 
Pomtlve abserptlon  Negative abserptlon 
Autologous  Allogenetc  Allogenelc 
Cultured melanoma cells  Cultured melanoma cells  Normal cells 
SK-MEL-27 (AT)  SK-MEL-13 ~AH)  Pooled leukocytes 
Cultured normal cells  SK-MEL-23 (AP)  Pooled tonsil  leukocytes 
AT fibroblasts  SK-MEL-28 (AU)  Xenogenelc 
Normal cells  SK-MEL-29 ~AV)  Cultured monkey kldney cells 
Leukocytes  MeWo  (BI)  Cultured chmken fibroblaets 
Platelets  Cultured nonmelanoma cells  Cultured mouse fibroblasts 
Allogenelc  T-24 (bladder ca)  Mouse spleen cells 
Cultured normal cells 
AU fibreblasts 
Autologous normal cells 
Erythrocytes 
Allogenelc normal cells 
Erythrocytes 
Xenogenelc cells  and serum 
Sheep erythrocytes 
Fetal bovine serum 
Mouse erythrocytes 
rally  or as a  consequence of transfusion or pregnancy.  When autologous reac- 
tions are observed, absorption analysis provides the means to test other autolo- 
gous  cells  as  well  as  allogeneic  and xenogeneic  cells  for corresponding  anti- 
gen. ~ Table  IV  summarizes  the  characteristics  of the  seven  surface  antigens 
which have now been recognized on melanoma cells through application of this 
serological  approach,  and  for  purposes  of  classification,  three  categories  of 
melanoma surface antigens can be distinguished:  (a) unique melanoma-specific 
antigens; restricted to autologous melanoma (e.g.,  AU, BI, and BD); (b) shared 
melanoma-specific  antigens;  found on some  (but not all)  allogeneic  melanoma 
cells, but not on other normal or malignant tissues (e.g.,  AH); and (c) antigens 
not restricted  to melanoma cells  (e.g.,  AV,  AN,  and AT).  The  autoantibodies 
that detect this last category  of surface  antigens  have a  surprisingly  complex 
pattern  of reactivity  as  revealed  by  absorption  tests.  For  instance,  anti-AV 
shows autoreactivity  (absorbed by autologous melanoma and fibroblasts),  allo- 
reactivity  (absorbed  by  melanoma  and  corresponding  fibroblasts  from  some 
individuals  but  not  from  others),  and  xenoreactivity  (absorbed  by  monkey, 
mouse, and chicken tissues).  In addition, the antigen  (or antigens) detected by 
anti-AV shows the characteristics  of a differentiation antigen, being present on 
1 For  a  consideration  of typing of melanoma  surface antigens  by absorption  tests,  see  refer- 
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TABLE  IV 
Cell Surface Antigens  of Human Mahgnant Melanomas Defined by 
Absorption  Tests with Autologous Serum 
Antlgen system  AU*  BI*  BD§  AH§  AV  AN  AT 
Serologlcal  test  MHA  MHA  IA  IA  IA  IA  MHA 
Absorbed  with 
Autologous cells 
Cultured  melanoma cells  +  +  +  +  +  +  + 
Cultured skin fibmblasts  -  -  +  + 
Lymphosd cells  -  -  + 
Erythrocytes  -  -  - 
Allogenelc  cells  and serum 
Cultured  melanoma  cells  -  -  -  +  or  -  +  or  -  +  or  -  + 
Cultured skin fibmblasts  -  -  +  or  -  +  or  --  + 
Cultured nonmelanoma  cells  ....  +  +  or  -  + 
Lymphmd cells  -  -  -  +  + 
Erythrocytes  .... 
Serum  -  -  - 
Xenogenelc cells  and serum 
Cultured monkey kidney cells  -  -  +  +  + 
Cultured chicken fibroblasts  -  -  -  +  + 
Cultured mouse fibrohlasts  -  -  +  -  + 
Mouse spleen cells  -  -  +  + 
Mouse erythrocytes 
Sheep erythrocytes  -  - 
Fetal  bovine  serum  -  -  -  -  - 
Claselficatlon  of antigen  Melanoma  Melanoma  Melanoma  Melanoma  Not mela-  Non mela-  Not mela- 
specific  spech~c  specific  specific  noma  noma  noma 
mdtvldual  lndtwdual  mdlwdual  shared  speclfic  specific  specific 
some  cell  types  but  not  on  others  from the  same  individual.  Anti-AN  has  a 
similarly  broad and complex reactivity,  but absorption analysis  shows that it 
detects different specificities than anti-AV. The antigen detected by anti-AT has 
the widest distribution of all. Nucleated cells from human, mouse, monkey, and 
chicken absorb anti-AT activity.  Only erythrocytes appear to lack AT antigen. 
What leads to the formation of these broadly reactive  autoantibodies to cell 
surface components of nucleated cells,  how frequently will they be detected in 
patients  with  melanoma  and  other  disease  states,  and  can  they  bring  about 
tissue injury? Autoantibodies to various constituents of normal cells are known 
to  occur  with  increased  frequency  in  patients  with  cancer  and  are  generally 
thought to arise as a consequence of antibody to tumor products that cross-react 
with normal tissues (3-6). In this regard, it may be of importance that the three 
melanoma  patients  with  the  broadly  reactive  antibodies  (AV,  AN,  AT)  had 
undergone chemotherapy,  whereas patients AU,  BD, and AH with melanoma- 
specific  antibody had not.  The possibility  that chemotherapy  with consequent 
tissue injury leads to an augmented or abnormal immune response to normal 
cellular components is now being directly investigated. 
Recognition of this class of autoantibodies to cell surface components present 
on both normal and malignant cells adds yet another complication to the search 
for characteristic  antigens of human cancer.  For instance,  several past studies 
have claimed tumor specificity on the basis of serological reactions with malig- 
nant cells but not with normal fibroblasts from the same individuals.  We now SHIKU  ET  AL.  BRIEF  DEFINITIVE  REPORT  789 
see that this sort of control is inadequate; AV and AT fibroblasts did not react 
with autologous serum in direct tests, but could remove reactivity for autologous 
melanoma cells in absorption tests. Nor can absorption with peripheral lympho- 
cytes, a  convenient source of normal cells,  be depended upon to prove tumor 
specificity even in autologous systems; anti-AV's reactivity for autologous mela- 
noma was not removed by autologous lymphocytes, but was absorbed by fibro- 
blasts. As these autoantibodies may arise unexpectedly, it cannot be assumed 
that sequential serum specimens drawn from the same patient,  even over a 
short  period  of time,  will  be  detecting  the  same  specificities.  The  possible 
presence  of these broadly reactive antibodies to cell surface components will 
have to be taken into consideration when monitoring and interpreting changes 
in serological reactivity of patients to autologous cancer cells. 
Summary 
The sera of three patients with malignant melanoma showing rectivity with 
surface antigens of cultured autologous melanoma cells were analyzed by mixed 
hemadsorption and immune adherence assays in conjunction with absorption 
tests.  In contrast to the melanoma-specific antigens demonstrated previously, 
the  surface  antigens  detected  by  these  sera  occurred  on  a  broad  range  of 
nucleated cells, both normal and malignant, from human, monkey, mouse, and 
chicken sources. Each serum had a characteristic pattern of  reactivity in absorp- 
tion  tests,  indicating the  detection  of distinct  antigenic  systems.  Two  sera 
showed auto-, allo-, and xenoreactivity, as well as the capacity to distinguish 
different cell populations in the same individual. The other serum reacted with 
an antigen apparently universally present on nucleated cells from a variety of 
species, but absent on erythrocytes. As these patients had been treated with 
chemotherapy, this may have played a  role in the emergence of these broadly 
reactive autoantibodies. 
We thank  Doctors  Y.  Kodera and  M.  A.  Bean,  Virginia Mason Research Center,  Seattle, for 
kindly providing us with sera from patient BI, Doctors  P.  O. Livingston and T. Carey for their 
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